Artivion is a medical device and tissue processing company focused on treating aortic disease, including aneurysms, dissections, and heart valve disease. Its products are used by cardiac and vascular surgeons in open and minimally invasive procedures. Artivion operates two segments: Medical Devices (the majority of revenue) and Preservation Services. The Medical Devices segment includes aortic stent grafts, On-X mechanical heart valves, and BioGlue surgical sealant. Stent grafts are the largest and fastest-growing product line, spanning abdominal, thoracic, and aortic arch repair. On-X is a mechanical heart valve with a unique FDA-approved low-dose warfarin indication, which no competing valve holds. BioGlue is a mature, high-margin surgical adhesive. Preservation Services involves processing donated human cardiac and vascular tissue for transplantation. Artivion sells directly to hospitals and surgeons in the U.S. and key European markets, and through distributors elsewhere. Revenue is driven by procedure volumes, product mix, and geographic penetration. Artivion's growth strategy centers on sequentially launching FDA-approved products in the U.S. and Japan, primarily devices already on the market in Europe. Key near-term drivers include expanding AMDS — an aortic arch remodeling device for acute Type A dissection — in the U.S., growing On-X into younger patients where clinical data favors mechanical over bioprosthetic valves, and a potential acquisition of Endospan upon FDA approval of NEXUS, an endovascular arch stent graft system.